Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10153
mi
from
Aventura, FL
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10153
mi
from
Aventura, FL
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 1345
mi
from
Miami, FL
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 1345
mi
from
Miami, FL
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10064
mi
from
Ormond Beach, FL
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10064
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
Savannah, GA
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 11501
mi
from
Overland Park, KA
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 11501
mi
from
Overland Park, KA
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10073
mi
from
Wichita, KA
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10073
mi
from
Wichita, KA
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10158
mi
from
Bethesda, MD
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10158
mi
from
Bethesda, MD
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10138
mi
from
North Dartmouth, MA
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10138
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10531
mi
from
Plymouth, MN
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10531
mi
from
Plymouth, MN
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
St. Louis, MO
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10642
mi
from
Bozeman, MT
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10642
mi
from
Bozeman, MT
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10105
mi
from
High Point, NC
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10105
mi
from
High Point, NC
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
Raleigh, NC
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10522
mi
from
Canton, OH
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10522
mi
from
Canton, OH
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
Cincinnati, OH
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
Oklahoma City, OK
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
Tulsa, OK
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10132
mi
from
Eugene, OR
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10132
mi
from
Eugene, OR
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
Medford, OR
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
Portland, OR
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 1366
mi
from
Charleston, SC
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 1366
mi
from
Charleston, SC
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10517
mi
from
Spartanburg, SC
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10517
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
Dallas, TX
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10149
mi
from
New Braunfels, TX
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10149
mi
from
New Braunfels, TX
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
San Antonio, TX
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
eRT Remote Health Monitoring
Feasibility and Cost Effectiveness of Physiological Monitoring at Home in COPD Patients
Status: Enrolling
Updated:  6/28/2013
UCLA David Geffen School of Medicine
mi
from
Los Angeles, CA
eRT Remote Health Monitoring
Feasibility and Cost Effectiveness of Physiological Monitoring at Home in COPD Patients
Status: Enrolling
Updated: 6/28/2013
UCLA David Geffen School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  7/9/2013
Novartis Investigative Site
mi
from
Birmingham, AL
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 7/9/2013
Novartis Investigative Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  7/9/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 7/9/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  7/9/2013
Novartis Investigative site
mi
from
Los Angeles, CA
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 7/9/2013
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  7/9/2013
Novartis Investigative Site
mi
from
Miami, FL
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 7/9/2013
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  7/9/2013
Novartis Investigative Site
mi
from
Las Vegas, NV
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 7/9/2013
Novartis Investigative Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  7/9/2013
Novartis Investigative Site
mi
from
High Point, NC
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 7/9/2013
Novartis Investigative Site
mi
from
High Point, NC
Click here to add this to my saved trials
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  7/9/2013
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 7/9/2013
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  7/9/2013
Novartis Investigative Site
mi
from
Knoxville, TN
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 7/9/2013
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  7/9/2013
Novartis Investigative site
mi
from
Dallas, TX
NVA237 Versus Placebo 12-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 7/9/2013
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of Alveolar Macrophages in Individuals With COPD Versus Smokers With Normal Pulmonary Function
Innate and Adaptive Immunity in COPD Exacerbations: Clinically-Indicated Bronchoscopies
Status: Enrolling
Updated:  7/15/2013
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Comparison of Alveolar Macrophages in Individuals With COPD Versus Smokers With Normal Pulmonary Function
Innate and Adaptive Immunity in COPD Exacerbations: Clinically-Indicated Bronchoscopies
Status: Enrolling
Updated: 7/15/2013
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
TruFreeze™ Airway Obstruction: TAO STUDY
A PROSPECTIVE, MULTI-CENTER PILOT STUDY OF THE truFREEZE™ SYSTEM TO ASSESS THE EFFICACY AND SAFETY OF CRYO SPRAY ABLATION IN THE TREATMENT OF AIRWAY OBSTRUCTIONS (TruFreeze AIRWAY OBSTRUCTION - "TAO" STUDY)
Status: Enrolling
Updated:  7/19/2013
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
TruFreeze™ Airway Obstruction: TAO STUDY
A PROSPECTIVE, MULTI-CENTER PILOT STUDY OF THE truFREEZE™ SYSTEM TO ASSESS THE EFFICACY AND SAFETY OF CRYO SPRAY ABLATION IN THE TREATMENT OF AIRWAY OBSTRUCTIONS (TruFreeze AIRWAY OBSTRUCTION - "TAO" STUDY)
Status: Enrolling
Updated: 7/19/2013
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
TruFreeze™ Airway Obstruction: TAO STUDY
A PROSPECTIVE, MULTI-CENTER PILOT STUDY OF THE truFREEZE™ SYSTEM TO ASSESS THE EFFICACY AND SAFETY OF CRYO SPRAY ABLATION IN THE TREATMENT OF AIRWAY OBSTRUCTIONS (TruFreeze AIRWAY OBSTRUCTION - "TAO" STUDY)
Status: Enrolling
Updated:  7/19/2013
Franklin Square Medical Center
mi
from
Baltimore, MD
TruFreeze™ Airway Obstruction: TAO STUDY
A PROSPECTIVE, MULTI-CENTER PILOT STUDY OF THE truFREEZE™ SYSTEM TO ASSESS THE EFFICACY AND SAFETY OF CRYO SPRAY ABLATION IN THE TREATMENT OF AIRWAY OBSTRUCTIONS (TruFreeze AIRWAY OBSTRUCTION - "TAO" STUDY)
Status: Enrolling
Updated: 7/19/2013
Franklin Square Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
TruFreeze™ Airway Obstruction: TAO STUDY
A PROSPECTIVE, MULTI-CENTER PILOT STUDY OF THE truFREEZE™ SYSTEM TO ASSESS THE EFFICACY AND SAFETY OF CRYO SPRAY ABLATION IN THE TREATMENT OF AIRWAY OBSTRUCTIONS (TruFreeze AIRWAY OBSTRUCTION - "TAO" STUDY)
Status: Enrolling
Updated:  7/19/2013
Boston Med Center
mi
from
Boston, MA
TruFreeze™ Airway Obstruction: TAO STUDY
A PROSPECTIVE, MULTI-CENTER PILOT STUDY OF THE truFREEZE™ SYSTEM TO ASSESS THE EFFICACY AND SAFETY OF CRYO SPRAY ABLATION IN THE TREATMENT OF AIRWAY OBSTRUCTIONS (TruFreeze AIRWAY OBSTRUCTION - "TAO" STUDY)
Status: Enrolling
Updated: 7/19/2013
Boston Med Center
mi
from
Boston, MA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
*See Various Dept.'s*, AZ
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
*See Various Dept.'s*, AZ
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Chandler, AZ
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Fresno, CA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Fresno, CA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Fullerton, CA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Yorba Linda, CA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Yorba Linda, CA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Yorba Linda, CA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Yorba Linda, CA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Boulder, CO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Boulder, CO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Wheat Ridge, CO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Lynn Haven, FL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Lynn Haven, FL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Miami, FL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Port Orange, FL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Port Orange, FL
Click here to add this to my saved trials